ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Cancers · 28.12.2023 · 16 (1) · 154
DOI: 10.3390/cancers16010154 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.12.2023. Verfasst von Andrea Duminuco und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit with BMT, A.O.U. Policlinico "G.Rodolico-San Marco", 95123 Catania, Italy. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute (National Institutes of Health).
Abstract (Originalsprache)
Activin receptor type I (ACVR1) is a transmembrane kinase receptor belonging to bone morphogenic protein receptors (BMPs). ACVR1 plays an important role in hematopoiesis and anemia via the BMP6/ACVR1/SMAD pathway, which regulates expression of hepcidin, the master regulator of iron homeostasis. Elevated hepcidin levels are inversely associated with plasma iron levels, and chronic hepcidin expression leads to iron-restricted anemia. Anemia is one of the hallmarks of myelofibrosis (MF), a bone marrow (BM) malignancy characterized by BM scarring resulting in impaired hematopoiesis, splenomegaly, and systemic symptoms. Anemia and red blood cell transfusions negatively impact MF prognosis. Among the approved JAK inhibitors (ruxolitinib, fedratinib, momelotinib, and pacritinib) for MF, momelotinib and pacritinib are preferably used in cytopenic patients; both agents are potent ACVR1 inhibitors that suppress hepcidin expression via the BMP6/ACVR1/SMAD pathway and restore iron homeostasis/erythropoiesis. In September 2023, momelotinib was approved as a treatment for patients with MF and anemia. Zilurgisertib (ACVR1 inhibitor) and DISC-0974 (anti-hemojuvelin monoclonal antibody) are evaluated in early phase clinical trials in patients with MF and anemia. Luspatercept (ACVR2B ligand trap) is assessed in transfusion-dependent MF patients in a registrational phase 3 trial. Approved ACVR1 inhibitors and novel agents in development are poised to improve the outcomes of anemic MF patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Unit with BMT, A.O.U. Policlinico "G.Rodolico-San Marco", 95123 Catania, Italy.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX 77030, USA.
- Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.
- Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
ORCID-Profile: Andrea Duminuco, Helen T Chifotides, Sebastiano Giallongo, Daniele Tibullo, Giuseppe A Palumbo
Förderung
- NCI NIH HHS
- National Cancer Institute (National Institutes of Health)
Zitieren
APA
Duminuco, A., Chifotides, H. T., Giallongo, S., Giallongo, C., Tibullo, D., & Palumbo, G. A. (2023). ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis. Cancers, 16(1), 154. https://doi.org/10.3390/cancers16010154
Vancouver
Duminuco A, Chifotides HT, Giallongo S, Giallongo C, Tibullo D, Palumbo GA. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis. Cancers. 2023;16(1):154. doi:10.3390/cancers16010154
BibTeX
@article{Duminuco2023,
author = {Duminuco, Andrea and Chifotides, Helen T and Giallongo, Sebastiano and Giallongo, Cesarina and Tibullo, Daniele and Palumbo, Giuseppe A},
title = {ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis},
journal = {Cancers},
year = {2023},
volume = {16},
number = {1},
pages = {154},
doi = {10.3390/cancers16010154}
}
EUVIMED